Glioblastoma, Glioma, Malignant
Conditions
Keywords
cilia disassembly complex, Nek2, glioblastoma stem cells
Brief summary
The study aims at investigating the cilium-related transcriptome in patients-derived glioblastoma stem cells and the potential impact of modulation of cilium players in vitro, in vivo and ex vivo in glioblastoma brain organoids. Moreover, drugs inhibiting cilia disassembly will be tested. Finally, the potential prognostic role of a cilium-related gene expression signature in glioblastoma will be assessed.
Interventions
OTHERBiological sample collection
Collection of tumor tissue and blood for stem cell culture and organoids generation.
OTHERDissecting ciliogenesis players
Assessment of cilium-related transcriptome in glioblastoma stem cells. Modulation of cilium-related genes and administration of cilium-targeted drugs to glioblastoma stem cells in vitro and ex vivo in glioblastoma brain organoids.
DIAGNOSTIC_TESTValidating ciliogenesis players
Cilium-related signature will be studied in tumor tissue to evaluate its prognostic role.
Sponsors
Istituto Superiore di Sanità
Fondazione C.N.R./Regione Toscana G. Monasterio, Pisa, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
To be enrolled in the study patients must: 1. Have a radiological diagnosis of supratentorial glioblastoma, or 2. Have a radiological diagnosis of first recurrence of a primary supratentorial glioblastoma (for which a formal histopathologic diagnosis of glioblastoma had been made at first surgery), according with RANO criteria (Wen, 2010); 3. Be a candidate to neurosurgery for glioblastoma at the Operational Unit of Neurosurgery FPG; 4. Be of an age of 18 years or above; 5. Provide written informed consent for participation to the study.
Exclusion criteria
To be enrolled in the study patients must not: 1. Have not enough pathological material removed at surgery available both for mandatory routine histopathological diagnosis and for the present study, as judged by the Principal Investigator; 2. Have not a definitive pathological diagnosis of a primary supratentorial GBM, according with 2016 WHO classification.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Biological | Through study completion, an average of 2 years | Correlation between modulation of cilia disassembly complex genes, and tumor growth and invasion in brain organoids. |
Countries
Italy
Outcome results
None listed